Catalog No. | HV599016 |
---|---|
Species reactivity | Human |
Applications | Research Grade Biosimilar |
Host species | Human |
Isotype | IgG1-kappa |
Expression system | Mammalian Cells |
Clonality | Monoclonal |
Target | BR3, TNFRSF13C, BAFF receptor, BLyS receptor 3, Tumor necrosis factor receptor superfamily member 13C, CD268, B-cell-activating factor receptor, BAFFR, BAFF-R |
Concentration | 1.1mg/ml |
Endotoxin level | Please contact the lab for this information. |
Purity | >95% purity as determined by SDS-PAGE. |
Purification | Protein A/G, purified from cell culture supernatant. |
Accession | Q96RJ3 |
Form | Liquid |
Storage buffer | 0.01M PBS,pH7.4. |
Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -220°C. |
Alternate Names | VAY-736,CAS:1929549-92-7 |
Background | Ianalumab (VAY-736) is a human, decarboxylated antibody against BAFF-R. Ianalumab can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF. Ianalumab exerts antibody-dependent cytotoxic (ADCC), depending on effector cell activation mediated by immune receptor tyrosine activation motif (ITAM). |
Note | For research use only. Not for use in clinical or therapeutic applications. |
SEC-HPLC detection for Research Grade Ianalumab.
Detects CD268/TNFRSF13C in indirect ELISAs.
+33(0)3 90 20 54 70
19 rue de la Haye 67300 Schiltigheim France